Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
copanlisib + rituximab
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Combination of copanlisib, a **pan-class I PI3K inhibitor** predominantly targeting PI3K-α and PI3K-δ, and rituximab, a monoclonal antibody against CD20 on B cells. Used primarily for **relapsed indolent non-Hodgkin lymphoma**, this regimen was shown in the CHRONOS-3 phase III trial to significantly prolong progression-free survival and increase response rates compared to rituximab with placebo, with improved outcomes in follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma[1][4]. Copanlisib disrupts B cell receptor and PI3K pathway survival signaling, countering resistance mechanisms in B-cell malignancies, while rituximab induces antibody-dependent cellular cytotoxicity and complement-mediated lysis[1][2][8]. The combination is delivered intravenously; common adverse events include transient hyperglycemia and hypertension[1].
- Other names
- copanlisib + rituximab
02
Targets
CD20 (B-lymphocyte antigen CD20)PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CD (Phosphatidylinositol 3-kinase delta)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)
Beyond the preview
Go deeper on copanlisib + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on copanlisib + rituximab.